Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of rituximab in patients with rheumatoid arthritis after inadequate response to TNF-alpha inhibitors
2006-001000-37Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of rituximab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Change of DAS28 at week 24. Started Jun 2006; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2006-001000-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001000-37.